在ALLEGRO临床开发计划中,在接受Ritlecitinib治疗的白发症患者中,临床反应的模式
B King1, P Mirmirani2, K Lo Sicco3
1Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA.
Journal of the European Academy of Dermatology and Venereology : JEADV
|February 17, 2025
概括
利特利西替尼治疗白发症 (AA) 显示,大约45%的患者实现了显著的头发再生. 延长治疗时间至关重要,因为一些患者需要一年以上才能看到反应.
科学领域:
- 药理学 药理学是指药理学的学科.
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 利特利西提尼布是一种口服的JAK3/TEC家族激酶抑制剂,在48周的时间里,它在脱毛率大 (AA) 中表现出有效性.
- 在ALLEGRO第2b/3期研究中,在AA患者中提供了利特列西尼布的初始疗效数据.
研究的目的:
- 为了评估长期的脱发严重程度工具 (SALT) 评分轨迹,在接受50毫克里特利西提尼布治疗的患者中进行评分.
- 为了确定与治疗响应相关的基线特征,在白发症地区.
主要方法:
- 对来自ALLEGRO第2b/3期和ALLEGRO-LT研究的患者进行了后期分析.
- 根据SALT评分响应 (早期,中期,晚期,部分,复发者,不响应者) 来对患者进行分类,长达24个月.
- 多变量逻辑回归用于识别与治疗反应相关的因素.
主要成果:
- 大约45.5%的患者是反应者 (SALT得分≤20),其中93.1%的患者维持了反应.
- 近一半 (46.0%) 的受访者获得了完整的反应 (SALT分数为0).
- 与反应相关的因素包括女性性别和较少的,较短时间的脱发.
结论:
- 大约有45%的患者在50毫克里特利西替尼治疗后实现了显著的头发再生.
- 显著比例的响应者 (高达11%) 需要超过一年的治疗才能达到他们的响应.
- 延长治疗时间对于最大限度地提高治疗效益是很重要的.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...